Novo Nordisk to begin Phase IIIa for Degludec-Victoza combination in diabetes
This article was originally published in Scrip
Executive Summary
Novo Nordisk is to start a pivotal Phase IIIa trial this month of its combination diabetes product, Degludec-Victoza (NN9068), it announced on 5 May at its capital markets day.